Viking Therapeutics Insider Buys $149,912 in Stock

Insider Neil William Aubuchon acquired 4,475 shares of the biotech company's stock.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Viking Therapeutics, Inc. (NASDAQ:VKTX) insider Neil William Aubuchon acquired 4,475 shares of the company's stock in a transaction on Tuesday, March 10th. The shares were purchased at an average cost of $33.50 per share, for a total transaction of $149,912.50. Following the completion of the transaction, the insider now owns 4,475 shares in the company, valued at approximately $149,912.50.

Why it matters

Insider buying can be seen as a positive signal, as it suggests the insider believes the stock is undervalued and has confidence in the company's future prospects. Viking Therapeutics is a clinical-stage biotech focused on developing novel therapies for metabolic and endocrine disorders.

The details

The transaction represents a significant increase in Aubuchon's position in the company. Viking Therapeutics' stock traded up $1.05 on Tuesday, reaching $34.66. The company's shares have traded in a 52-week range of $18.92 to $43.15, with a current average price of $31.79.

  • The transaction took place on Tuesday, March 10th, 2026.

The players

Neil William Aubuchon

An insider at Viking Therapeutics, Inc. who acquired 4,475 shares of the company's stock.

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

Got photos? Submit your photos here. ›

The takeaway

This insider purchase suggests the insider has confidence in Viking Therapeutics' future prospects and believes the stock is currently undervalued. As a clinical-stage biotech, the company's success will depend on the progress of its pipeline of novel drug candidates targeting metabolic and endocrine disorders.